Bill Murray is stepping down as CEO of the Medical Device Innovation Consortium on Feb. 2, but he will be helping the group during the leadership transition period, and says he's excited about several long-term projects, including one designed to help better understand the evidence requirements sponsors should consider in pre-market trials to satisfy Medicare requirements. Murray spoke to Medtech Insight; read about it and listen to the podcast interview.

The US Centers for Medicare and Medicaid Services has withdrawn efforts on a proposed rule to offer faster Medicare reimbursement to novel devices, but the agency still plans to work on different approaches to provide "timely patient access" to device innovations, a spokeswoman said. AdvaMed says it is disappointed by CMS's decision to withdraw the rule after a 10-month review by the Office of Management and Budget.

There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.